Get the Stockscreener App
929.55
0.98%
-9.92
After Hours:
930.00
0.45
+0.05%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $929.55, with a volume of 1.57M.
It is down -0.98% in the last 24 hours and down -5.57% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$939.47
Open:
$939.97
24h Volume:
1.57M
Relative Volume:
0.51
Market Cap:
$830.07B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
41.15
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
+0.35%
1M Performance:
-5.57%
6M Performance:
+13.53%
1Y Performance:
+27.01%
1-Day Range:
$927.17
$945.90
1-Week Range:
$898.45
$963.94
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
929.16 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
237.81 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.47 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.26 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.11 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Insilico CEO sees potentially $2.75 billion collaboration as 'fusing Lilly’s clinical excellence' with Insilico's 'end-to-end AI engine' - drugdiscoverytrends.com
Lilly's Jaypirca significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL - Investing News Network
How Eli Lilly Stock Rises To $2,000 - Trefis
Fund Update: 25,865 ELI LILLY (LLY) shares added to LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP|MA portfolio - Quiver Quantitative
Auto-Callable Geared Buffer Notes on Eli Lilly (RBMCF) with Memory Coupon - Stock Titan
Eli Lilly Stock (LLY) Gets Shot in the Arm from New Leukemia Drug - TipRanks
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock? - Yahoo Finance
Eli Lilly (LLY) Reports Promising Phase 3 Results for Jaypirca i - GuruFocus
What's Going On With Eli Lilly Stock Monday?Eli Lilly (NYSE:LLY) - Benzinga
Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off - TradingView — Track All Markets
Lilly’s Jaypirca shows improved survival in CLL trial By Investing.com - Investing.com South Africa
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,280 - 富途牛牛
Eli Lilly (LLY) Reports Positive Trial Results for Jaypirca in C - GuruFocus
Even After Shedding Some Weight, Eli Lilly and Company Isn't Prime For Upgrade (NYSE:LLY) - Seeking Alpha
Eli Lilly & Co (NYSE:LLY) Presents a Prime Case for Affordable Growth Investing - ChartMill
Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034 - GlobeNewswire Inc.
Eli Lilly's Q1 GLP-1 Sales to Exceed Market Expectations, RBC Says - 富途牛牛
Mounjaro maker Lilly eyes India rollout for oral obesity drug orforglipron - Moneycontrol.com
Eli Lilly Balances India GLP-1 Generics Shock With Foundayo U.S. Push - simplywall.st
After Receiving the Green Light for Its Weight Loss Medication, Is Eli Lilly Stock Set for Rapid Growth? - Bitget
Yousif Capital Management Trims Stake in Eli Lilly - National Today
Eli Lilly's Dual-Pronged Strategy: A Pill Launch and a $6.3 Billion Bet - AD HOC NEWS
Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide StrategyNews and Statistics - IndexBox
Jackson Square Capital LLC Boosts Eli Lilly and Company Holdings - National Today
🚨 In case you missed it, we broke down one of the most significant shifts happening in biotech right now. Eli Lilly and Company is using LillyPod and AI to aggressively accelerate drug discovery timelines and reshape how research and development works at s - LinkedIn
BIP Wealth LLC Boosts Eli Lilly Stake by 161% - National Today
Assessing Eli Lilly (LLY) Valuation After A 13% Year To Date Share Price Pullback - simplywall.st
FDA Approves Eli Lilly's New Weight-Loss Pill: Foundayo Explained - National Today
Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - The Motley Fool
Steadtrust LLC Acquires 1,197 Shares in Eli Lilly - National Today
Steadtrust LLC Acquires $1.3M Stake in Eli Lilly - National Today
Eli Lilly Price Target Raised to $880 by Rothschild & Co Redburn - National Today
Foundayo Explained: Lilly’s New Weight Loss Pill And The Amazon Effect (NYSE:LLY) - Seeking Alpha
Eli Lilly and Co (WAR:LILY) Beta : N/A (As of Apr. 11, 2026) - GuruFocus
LLY Stock Quote Price and Forecast - CNN
Eli Lilly's Weight-Loss Pill Debuts Amid Shifting Market Dynamics - AD HOC NEWS
RBC Capital reiterates Eli Lilly stock rating on GLP-1 strength - Investing.com Canada
Stock Quote & Chart - Eli Lilly
Western Financial Corp CA Boosts Stake in Eli Lilly - National Today
Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader - 24/7 Wall St.
Eli Lilly's Foundayo Forges New Path with Amazon as Political Headwinds Bite - AD HOC NEWS
Eli Lilly (LLY) Analyst Ratings Data: April 2026 Updates | LLY S - GuruFocus
Amazon Pharmacy adds same-day delivery for Eli Lilly's Foundayo weight-loss pill - qz.com
With oral obesity race underway, all eyes are on Lilly’s Foundayo launch - BioSpace
Eli Lilly (LLY) Expands Patient Access to Foundayo for Weight Ma - GuruFocus
LifeMD adds Eli Lilly’s oral weight loss drug to platform By Investing.com - Investing.com India
Amazon Pharmacy to offer Eli Lilly’s Foundayo via same-day delivery - Yahoo Finance
Eli Lilly loses weight loss drug market share as generics flood India - Yahoo Finance
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,327 - 富途牛牛
LifeMD adds Eli Lilly’s oral weight loss drug to platform - Investing.com
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management - The Manila Times
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):